RE: AGM Questions.Beech... good idea... and your previous list re Oppenheimer Healthcare conference (posted on Oct 29) is a good starting point re Urocidin.
As I also plan to attend... I will ask these two questions re Echoniche if not answered in their presentation:
1) Why the "continued" lengthy delay in obtaining a U.S conditional license for Econiche? Is there a reason for more certainty in regards to the statement on pg 4 of annual report re "conditional license in the U.S., which we hope to receive by calendar year-end"?
2) Is Bioniche actively "in search" / "in discussions" with a U.S. company for distribution of Econiche? Status? If not, what is the plan (given expectation of receiving a conditional license in the U.S.)?
Thanks, rg